Home / Recalls / Mylan Institutional, Inc. / D-0133-2025

D-0133-2025 Class II Ongoing

Recalled by Mylan Institutional, Inc. — Rockford, IL

Recall Details

Product Type
Drugs
Report Date
December 18, 2024
Initiation Date
November 19, 2024
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,664 cartons

Product Description

Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-443-20

Reason for Recall

Subpotent and Superpotent Drug

Distribution Pattern

Nationwide in the USA.

Code Information

Lot #: 3115893, Exp. Date 6/2025

Other recalls by Mylan Institutional, Inc.

  • D-0291-2025 Class II — Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), Rx Only, 100 Unit Dose Bl (March 7, 2025)
  • D-0290-2025 Class II — Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), Rx Only, 100 Unit Dose Bli (March 7, 2025)
  • D-0132-2025 Class II — Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 100 Tablets per carton (1 (November 19, 2024)
  • D-0131-2025 Class II — Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 100 Tablets per carton (10 (November 19, 2024)
  • D-0136-2025 Class II — Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 100 Tablets per carton (1 (November 19, 2024)
  • D-0134-2025 Class II — Levothyroxine Sodium Tablets, USP, 137 mcg (0.137 mg), 100 Tablets per carton (1 (November 19, 2024)
  • D-0135-2025 Class II — Levothyroxine Sodium Tablets, USP, 150 mcg (0.150 mg), 100 Tablets per carton (1 (November 19, 2024)
  • D-0601-2021 Class III — Thiamine HCl Injection, USP 200 mg/2 mL (100mg/mL), 2 mL vials, packaged in 25 ( (May 3, 2021)
  • D-1575-2020 Class I — Amiodarone Hydrochloride Injection, USP, 450 mg/9 mL (50 mg/mL), 9 mL Single-Dos (August 17, 2020)
  • D-1576-2020 Class I — Tranexamic Acid Injection, USP, 1000 mg/10 mL (100 mg/mL), 10 mL Single-Dose Via (August 17, 2020)